J. Stern & Co. LLP Buys 10,051 Shares of DexCom, Inc. $DXCM

Key Points

• J. Stern & Co. LLP increased its holdings in DexCom, Inc. by 36.4% during the first quarter, now owning 37,676 shares worth approximately $2.57 million.
• DexCom reported a 15.2% increase in revenue year-over-year, with $1.16 billion for the quarter and earnings per share beating estimates at $0.48.
• Recent analysts' ratings show a general optimism with a consensus target price of $99.89 and three analysts rating DexCom as a Strong Buy.

J. Stern & Co. LLP lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 36.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,676 shares of the medical device company's stock after acquiring an additional 10,051 shares during the period. DexCom makes up about 0.2% of J. Stern & Co. LLP's investment portfolio, making the stock its 28th largest holding. J. Stern & Co. LLP's holdings in DexCom were worth $2,573,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently made changes to their positions in DXCM. Golden State Wealth Management LLC increased its position in shares of DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after acquiring an additional 264 shares in the last quarter. Zions Bancorporation National Association UT bought a new stake in shares of DexCom during the first quarter worth $27,000. Optiver Holding B.V. bought a new stake in shares of DexCom during the fourth quarter worth $33,000. Heck Capital Advisors LLC bought a new stake in shares of DexCom during the fourth quarter worth $38,000. Finally, Alpine Bank Wealth Management bought a new stake in shares of DexCom during the first quarter worth $40,000. Institutional investors own 97.75% of the company's stock.

Insider Activity

In related news, EVP Michael Jon Brown sold 500 shares of the company's stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $80.29, for a total transaction of $40,145.00. Following the completion of the transaction, the executive vice president directly owned 94,102 shares in the company, valued at $7,555,449.58. This represents a 0.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Sadie Stern sold 1,466 shares of the company's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $88.99, for a total transaction of $130,459.34. Following the transaction, the executive vice president owned 106,689 shares of the company's stock, valued at approximately $9,494,254.11. This represents a 1.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 15,722 shares of company stock valued at $1,306,131 over the last quarter. 0.32% of the stock is owned by corporate insiders.

DexCom Stock Performance

Shares of NASDAQ DXCM traded up $0.26 during mid-day trading on Friday, reaching $75.34. 2,921,932 shares of the company were exchanged, compared to its average volume of 4,186,415. The company's 50-day simple moving average is $82.25 and its 200-day simple moving average is $79.44. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $29.54 billion, a P/E ratio of 52.32, a P/E/G ratio of 1.58 and a beta of 1.43. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.13 billion. During the same quarter last year, the company posted $0.43 EPS. DexCom's quarterly revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. As a group, research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on DXCM shares. Wall Street Zen cut shares of DexCom from a "strong-buy" rating to a "buy" rating in a report on Sunday, August 10th. The Goldman Sachs Group began coverage on shares of DexCom in a research note on Friday, May 30th. They issued a "buy" rating and a $104.00 price target for the company. Mizuho increased their price target on shares of DexCom from $95.00 to $100.00 and gave the company an "outperform" rating in a research note on Wednesday, July 16th. UBS Group increased their price target on shares of DexCom from $105.00 to $106.00 and gave the company a "buy" rating in a research note on Thursday, July 31st. Finally, Piper Sandler increased their price target on shares of DexCom from $90.00 to $100.00 and gave the company an "overweight" rating in a research note on Thursday, July 31st. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $99.89.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.